Current Treatment Options in Oncology

, Volume 4, Issue 1, pp 3–13

Oropharyngeal cancer: The role of chemotherapy

  • David J. Adelstein

Opinion statement

Successful management of squamous cell cancer of the oropharynx must address two, sometimes conflicting, treatment goals. The first goal is disease eradication, and the second is preservation of oropharyngeal function. For early cancers, definitive surgical excision often represents the most effective and least morbid approach. When surgery is likely to result in functional deficits of speech or swallowing, definitive radiation therapy can also be used successfully. Often the choice of treatment modality is based on institutional expertise and bias. However, for the more frequent patients with advanced disease, treatment choices become more complex. Historically, surgery and radiation therapy have been used together, often with suboptimal control of locoregional disease and significant long-term functional deficits, reflecting surgical excision, radiationinduced long-term toxicities, and any initial functional impairment resulting from the tumor. The addition of systemic chemotherapy to definitive radiation has now been demonstrated to produce a significant survival benefit for patients with advanced squamous cell head and neck cancer originating in the oropharynx and elsewhere. Although there are still specific indications for primary surgical resection, the use of chemotherapy and radiation has become a standard of care for the management of patients with this disease, with surgery often reserved for salvage of those who fail definitive nonoperative treatment. Debate continues as to the best tolerated and most successful combination of chemotherapy drugs, radiation fractionation schema, and coordination of treatment modalities; however, a reproducible survival benefit has been demonstrated only for the concomitant, platinum-based treatment schedules. The focus of future investigation must be on optimizing these multimodality approaches, minimizing toxicities and functional deficits while maximizing treatment success. It is hoped that the addition of the newer therapeutic approaches, including epidermal growth factor receptor inhibition and gene therapy, may further improve the results of more traditional treatment combinations. Continued enrollment of patients in well-designed and conducted clinical trials is of paramount importance.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Adelstein DJ: Oropharyngeal cancer: the role of the medical oncologist in organ-function conservation. Am Soc Clin Oncol Educ Book 1999:544–550.Google Scholar
  2. 2.
    List MA, Stracks J, Colangelo L, et al.: How do head and neck cancer patients prioritize treatment outcomes before initiating treatment? J Clin Oncol 2000, 18:877–884.PubMedGoogle Scholar
  3. 3.
    Fu KK, Pajak TF, Trotti A, et al.: A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003? Int J Radiat Oncol Biol Phys 2000, 48:7–16.PubMedCrossRefGoogle Scholar
  4. 4.
    Forastiere A, Koch W, Trotti A, et al.: Head and neck cancer? N Engl J Med 2001, 345:1890–1900. An excellent summary of recent advances in our understanding and treatment of this disease.PubMedCrossRefGoogle Scholar
  5. 5.
    Day GL, Blot WJ, Shore RE, et al.: Second cancers following oral and pharyngeal cancers: role of tobacco and alcohol? J Natl Cancer Inst 1994, 86:131–137.PubMedCrossRefGoogle Scholar
  6. 6.
    Adelstein DJ, Tan EH, Lavertu P: Treatment of head and neck cancer: the role of chemotherapy? Crit Rev Oncol Hematol 1996, 24:97–116.PubMedCrossRefGoogle Scholar
  7. 7.
    Forastiere AA, Metch B, Schuller DE, et al.: Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group Study? J Clin Oncol 1992, 10:1245–1251.PubMedGoogle Scholar
  8. 8.
    Jacobs C, Lyman G, Velez-Garcia E, et al.: A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck? J Clin Oncol 1992, 10:257–263.PubMedGoogle Scholar
  9. 9.
    Murphy B, Li Y, Cella D, et al.: Phase III study comparing cisplatin & 5-fluorouracil versus cisplatin & paclitaxel in metastatic/recurrent head and neck cancer [abstract]? Proc Am Soc Clin Oncol 2001, 20:224a.Google Scholar
  10. 10.
    Adelstein DJ: Induction chemotherapy in head and neck cancer? Hematol Oncol Clin North Am 1999, 13:689–698.PubMedCrossRefGoogle Scholar
  11. 11.
    Pignon JP, Bourhis J, Domenge C, et al.: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data? Lancet 2000, 355:949–955. Results of the most comprehensive meta-analysis of chemotherapy in the definitive management of head and neck cancer.PubMedGoogle Scholar
  12. 12.
    Domenge C, Hill C, Lefebvre JL, et al.: Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma? Br J Cancer 2000, 83:1594–1598. The only oropharynx-specific trial of neoadjuvant chemotherapy to demonstrate a survival benefit.PubMedCrossRefGoogle Scholar
  13. 13.
    Adelstein DJ: Recent randomized trials of chemoradiation in the management of locally advanced head and neck cancer? Curr Opin Oncol 1998, 10:213–218.PubMedGoogle Scholar
  14. 14.
    Lo TCM, Wiley AL, Ansfield FJ, et al.: Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study? Am J Roentgenol 1976, 126:229–235.Google Scholar
  15. 15.
    Adelstein DJ, Adams GL, Li Y, et al.: A phase III comparison of standard radiation therapy (RT) versus RT plus concurrent cisplatin (DDP) versus split-course RT plus concurrent DDP and 5-fluorouracil (5FU) in patients with unresectable squamous cell head and neck cancer (SCHNC): an Intergroup study [abstract]? Proc Am Soc Clin Oncol 2000, 19:411a.Google Scholar
  16. 16.
    Jeremic B, Shibamoto Y, Stanisavljevic B, et al.: Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial? Radiother Oncol 1997, 43:29–37.PubMedCrossRefGoogle Scholar
  17. 17.
    Adelstein DJ, Saxton JP, Lavertu P, et al.: A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results? Head Neck 1997, 19:567–575.PubMedCrossRefGoogle Scholar
  18. 18.
    Wendt TG, Grabenbauer GG, Rodel CM, et al.: Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study? J Clin Oncol 1998, 16:1318–1324.PubMedGoogle Scholar
  19. 19.
    Brizel DM, Albers ME, Fisher SR, et al.: Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer? N Engl J Med 1998, 338:1798–1804.PubMedCrossRefGoogle Scholar
  20. 20.
    Calais G, Alfonsi M, Bardet E, et al.: Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma? J Natl Cancer Inst 1999, 91:2081–2086. An important study that helped establish concurrent chemoradiotherapy as a standard of care in the management of oropharyngeal cancer.PubMedCrossRefGoogle Scholar
  21. 21.
    Staar S, Rudat V, Stuetzer H, et al.: Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy: results of a multicentric randomized German trial in advanced head and neck cancer? Int J Radiat Oncol Biol Phys 2001, 50:1161–1171.PubMedCrossRefGoogle Scholar
  22. 22.
    Forastiere AA, Trotti A: Radiotherapy and concurrent chemotherapy: a strategy that improves locoregional control and survival in oropharyngeal cancer? J Natl Cancer Inst 1999, 91:2065–2066.PubMedCrossRefGoogle Scholar
  23. 23.
    Vokes EE, Kies MS, Haraf DJ, et al.: Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer? J Clin Oncol 2000, 18:1652–1661.PubMedGoogle Scholar
  24. 24.
    Adelstein DJ, Saxton JP, Lavertu P, et al.: Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer with hyperfractionated radiation and concurrent chemotherapy? J Clin Oncol 2002, 20:1405–1410.PubMedCrossRefGoogle Scholar
  25. 25.
    Bachaud JM, Cohen-Jonathan E, Alzieu C, et al.: Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial? Int J Radiat Oncol Biol Phys 1996, 36:999–1004.PubMedCrossRefGoogle Scholar
  26. 26.
    Bernier J, Domenge C, Eshwege F, et al.: Chemoradiotherapy, as compared to radiotherapy alone, significantly increases disease-free and overall survival in head and neck cancer patients after surgery: results of EORTC phase III trial 22931 [abstract]? Int J Radiat Oncol Biol Phys 2001, 51:1.CrossRefGoogle Scholar
  27. 27.
    Cooper JS, Pajak TF, Forastiere AA, et al.: Postoperative concurrent radiochemotherapy in high risk SCCA of the head and neck: initial report of RTOG 9501/ Intergroup phase III trial [abstract]? Proc Am Soc Clin Oncol 2002, 21:226a.Google Scholar
  28. 28.
    Trotti A: Toxicity in head and neck cancer: a review of trends and issues? Int J Radiat Oncol Biol Phys 2000, 47:1–12.PubMedCrossRefGoogle Scholar
  29. 29.
    Arteaga CL: The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia? J Clin Oncol 2001, 19:32s-40s.PubMedGoogle Scholar
  30. 30.
    Clayman GL, Dreiling L: Local delivery for gene therapy? Curr Oncol Rep 1999, 1:138–143.PubMedCrossRefGoogle Scholar
  31. 31.
    Brizel DM, Wasserman TH, Henke M, et al.: Phase III randomized trial of amifostine as a radioprotector in head and neck cancer? J Clin Oncol 2000, 18:3339–3345.PubMedGoogle Scholar
  32. 32.
    LeVeque FG, Montgomery M, Potter D, et al.: A multicenter, randomized, double-blind placebocontrolled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients? J Clin Oncol 1993, 11:1124–1131.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2003

Authors and Affiliations

  • David J. Adelstein
    • 1
  1. 1.Department of Hematology & Medical OncologyThe Cleveland Clinic FoundationClevelandUSA

Personalised recommendations